Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis.
Strang AC, Bisoendial RJ, Kootte RS, Schulte DM, Dallinga-Thie GM, Levels JH, Kok M, Vos K, Tas SW, Tietge UJ, Müller N, Laudes M, Gerlag DM, Stroes ES, Tak PP.
Strang AC, et al. Among authors: vos k.
Atherosclerosis. 2013 Jul;229(1):174-81. doi: 10.1016/j.atherosclerosis.2013.04.031. Epub 2013 May 11.
Atherosclerosis. 2013.
PMID: 23746537
Clinical Trial.